TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 37001911
Drug: Mirikizumab 50
Normalized name: Mirikizumab
DrugBank: Mirikizumab (DB14910)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirikizumab 50 mg
Study: 37001911
Drug: Mirikizumab 200
Normalized name: Mirikizumab
DrugBank: Mirikizumab (DB14910)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirikizumab 200 mg
Study: 38947323
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy (NACT)
Study: 34548165
Drug: 1,000 mg
Normalized name: bran 1,000 mg ORAL WAFER
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,000 mg IV acetaminophen (group A)
Study: 33038017
Drug: Cosmetic treatment
Normalized name: Botox Cosmetic
DrugBank: DaxibotulinumtoxinA (DB17929)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cosmetic treatment product
Study: 35122085
Drug: Aspirin use
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin use ≤60 days/year
Study: 39696526
Drug: Nilotinib 300
Normalized name: Nilotinib
DrugBank: Nilotinib (DB04868)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nilotinib 300 mg twice daily
Study: 33457425
Drug: Insulin monotherapy
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin monotherapy
Study: 35217440
Drug: Tanezumab 5
Normalized name: tanezumab
DrugBank: Tanezumab (DB12335)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tanezumab 5 mg, subcutaneous every 8 weeks for 56 weeks
Study: 33909759
Drug: SHAM treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHAM treatment (control group)
Study: 36278416
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment group
Study: 36332560
Drug: Antibiotic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic therapy
Study: 36266762
Drug: risankizumab 600
Normalized name: RISANKIZUMAB 600 mg in 10 mL INTRAVENOUS INJECTION [Skyrizi]
Approvals — FDA: no, EMA: no, PMDA: no
Description: risankizumab 600 mg IV
Study: 36266762
Drug: risankizumab 1200
Normalized name: RISANKIZUMAB
DrugBank: Risankizumab (DB14762)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: risankizumab 1200 mg IV
Study: 36266762
Drug: risankizumab 360
Normalized name: RISANKIZUMAB 360 mg in 2.4 mL SUBCUTANEOUS INJECTION, SOLUTION [Skyrizi]
Approvals — FDA: no, EMA: no, PMDA: no
Description: risankizumab 360 mg SC
Study: 38622893
Drug: Endovascular treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular treatment
Study: 33800775
Drug: Virtual Reality
Normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Virtual Reality therapy and Mirror Therapy (MT)
Study: 33475935
Drug: Whole Body
Normalized name: MaxiVision Whole Body Formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole Body Vibration and Exercise Therapy (WBV + E)
Study: 39226076
Drug: Cognitive therapy
Normalized name: cognitive therapy software
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive therapy (CT)
Study: 33528862
Drug: Inhaled nitrous
Normalized name: nitrous oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled nitrous oxide (INO)
Study: 33528862
Drug: No analgesic
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: No analgesic
Study: 35667085
Drug: 1300 mg
Normalized name: gelatin 1300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1300 mg TXA orally or 1000 mg TXA IV thrice daily for maximum 30 days
Study: 34231490
Drug: Long-term antithyroid
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term antithyroid drug therapy (LTADT; >24 months of treatment)
Study: 34737296
Drug: Low-dose IL-2
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose IL-2 for 24 weeks
Study: 34438469
Drug: Low-dose colchicine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose colchicine
Study: 33858561
Drug: Traditional chemotherapy
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional chemotherapy
Study: 38476396
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy (CBT)
Study: 35279338
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (oxycodone, tramadol, and celecoxib)
Study: 35614473
Drug: All codeine
Normalized name: Codeine
DrugBank: Codeine (DB00318)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All codeine dose groups
Study: 39698942
Drug: Antibiotics
Normalized name: Antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics
Study: 32067262
Drug: ACT-539313 100
Normalized name: ACT-541468
DrugBank: Daridorexant (DB15031)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ACT-539313 100 mg in fasted conditions
Study: 32067262
Drug: ACT-539313 100
Normalized name: ACT-541468
DrugBank: Daridorexant (DB15031)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ACT-539313 100 mg in fed conditions
Study: 34656119
Drug: Clopidogrel 75
Normalized name: clopidogrel 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel 75 mg once daily
Study: 32804661
Drug: Non-cultured autologous
Normalized name: omidubicel
DrugBank: Omidubicel (DB17132)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-cultured autologous skin cell suspensions
Study: 38082273
Drug: Corticosteroid treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid treatment
Study: 39633319
Drug: Cognitive-behavioural therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioural therapy (CBT)
Study: 35746502
Drug: EV71 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EV71 vaccine administered simultaneously with other vaccines
Study: 35487526
Drug: Escalated dose
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escalated dose radiotherapy (62 Gy to primary tumour, 50.4 Gy to surrounding mesorectum in 28 fractions) with concurrent chemotherapy (capecitabine, 5-fluorouracil/leucovorin or omitted)
Study: 34965712
Drug: Rehabilitation complex
Normalized name: hesperidin complex
DrugBank: Citrus bioflavonoids (DB14586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rehabilitation complex including gravitational therapy and antiresorptive therapy
Study: 33818780
Drug: Treatment-emergent adverse
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment-emergent adverse events (TEAEs) with ubrogepant coadministered with erenumab or galcanezumab
Study: 32366927
Drug: Sildenafil citrate
Normalized name: Sildenafil Citrate
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sildenafil citrate (SIL, 50 mg twice daily)
Study: 37163686
Drug: EMLA cream
Normalized name: LIDOCAINE 25 mg in 1 g / PRILOCAINE 25 mg in 1 g TOPICAL CREAM [Emla Cream]
DrugBank: Prilocaine (DB00750)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EMLA cream
Study: 33989990
Drug: Manual therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual therapy based on articulatory techniques
Study: 39074480
Drug: Medical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical treatment only
Study: 32511143
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group received infiltration of 0.5% bupivacaine 100 mg (20 mL) and epinephrine 0.5 mg (0.5 mL)
Study: 34465809
Drug: Administration of
Normalized name: IV solutions used in parenteral administration of fluids, electrolytes and nutrients
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of recombinant human KAL (rhKAL)
Study: 32588047
Drug: Fortified milk
Normalized name: Fortified milk
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fortified milk supplement (2 × 30 g/d) and exercise program (2 × 1 h/wk including resistance, balance, and aerobic training)
Study: 32758087
Drug: Photobiomodulation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photobiomodulation therapy (PBMT) - 60 J per site, 6 sites per limb, total dose = 360 J
Study: 37702427
Drug: Mechanical bowel
Normalized name: ascorbic acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mechanical bowel preparation (MBP)
Study: 39407315
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy only
Study: 32985080
Drug: Intervention to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention to improve detection and treatment of depression in primary care patients receiving ART
Study: 35731889
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg of suvorexant
Study: 35829772
Drug: Chitosan gel
Normalized name: Chitosan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chitosan gel + 0.1 mg/mL CaneCPI-5 (Cg + Cane)
Study: 39405911
Drug: Metformin (MET)
Normalized name: metformin / pioglitazone Oral Tablet [Actoplus Met]
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin (MET)
Study: 33176725
Drug: Seribantumab (MM-121)
Normalized name: Seribantumab
DrugBank: Seribantumab (DB11857)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Seribantumab (MM-121) added to standard therapy
Study: 34603045
Drug: TRC150094 50
Normalized name: TRC150094
DrugBank: TRC150094 (DB16046)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TRC150094 50 mg
Study: 35295605
Drug: Methylprednisolone Pulses
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylprednisolone Pulses (MPP) 120 mg/day for 3 days
Study: 32907283
Drug: ACYW135 group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACYW135 group meningococcal conjugate vaccine
Study: 35991892
Drug: Intramuscular pethidine
Normalized name: pethidine
DrugBank: Meperidine (DB00454)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular pethidine (50 mg as required)
Study: 34622766
Drug: Vaccine group
Normalized name: MENINGOCOCCAL OLIGOSACCHARIDE VACCINE GROUP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine group
Study: 33250338
Drug: Open administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Open administration of antidepressant medication for 8 weeks
Study: 33383112
Drug: Estrogen vaginal
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen vaginal cream
Study: 35288320
Drug: Mechanical debridement
Normalized name: PIPERONYL BUTOXIDE TECHNICAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mechanical debridement (MD) followed by a single session of antimicrobial photodynamic therapy (aPDT)
Study: 32310005
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no acupuncture treatment)
Study: 33403428
Drug: 10 ml
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 ml 0.375% ropivacaine at T2, T5, and T8 levels
Study: 33134378
Drug: Most common
Normalized name: Common carp
DrugBank: Common carp (DB10614)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Most common antihypertensive medication class being taken
Study: 38240916
Drug: Tislelizumab 200
Normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tislelizumab 200 mg every 3 weeks
Study: 32434001
Drug: Pre-pregnancy platelet
Normalized name: platelet glycoprotein VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-pregnancy platelet factor 4 (tertile 3) in aspirin group
Study: 33297668
Drug: Induction therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction therapy with ASCT
Study: 33627077
Drug: TENS therapy
Normalized name: Walgreens Electronic TENS Therapy Pain Relief Pad
Approvals — FDA: no, EMA: no, PMDA: no
Description: TENS therapy during the first stage of labor
Study: 39352173
Drug: Treatment-as-usual (TAU)
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment-as-usual (TAU)
Study: 34343545
Drug: Routine oral
Normalized name: Peace Out Acne Hero Routine KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine oral care and medication
Study: 34650930
Drug: Bevacizumab monotherapy
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab monotherapy
Study: 34774225
Drug: Nivolumab 1
Normalized name: nivolumab 10 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab 1 mg/kg plus ipilimumab 3 mg/kg intravenously every 3 weeks for four doses, followed by nivolumab 3 mg/kg every 2 weeks for up to 2 years.
Study: 32663919
Drug: Professionally applied
Normalized name: Clearskin Professional Daily Correcting
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Professionally applied topical fluoride (DHSU‐PATF)
Study: 34189447
Drug: Telmisartan 80
Normalized name: telmisartan 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telmisartan 80 mg twice daily for 14 days
Study: 39023063
Drug: Oral anticoagulants
Normalized name: CPDA-1 Anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral anticoagulants (OAC)
Study: 34002406
Drug: Professional-guided bibliotherapy
Normalized name: Clearskin Professional Daily Correcting
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Professional-guided bibliotherapy sessions (8 weekly sessions)
Study: 36906081
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (Control)
Study: 33315720
Drug: Total parenteral
Normalized name: TPN - total parenteral nutrition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total parenteral nutrition
Study: 32147827
Drug: Synbiotic tablets
Normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Synbiotic tablets (T(+), T(-))
Study: 35835670
Drug: Continuous subcutaneous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous subcutaneous insulin infusion (CSII)
Study: 34511464
Drug: Tivortin aspartate
Normalized name: aspartate
DrugBank: Potassium aspartate (DB15819)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tivortin aspartate (40 ml daily for 14 days)
Study: 33162202
Drug: Maternal antibodies
Normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maternal antibodies
Study: 34234581
Drug: Early goal-directed
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early goal-directed therapy (EGDT) using FloTrac/EV1000 platform
Study: 36542287
Drug: Insulin peglispro
Normalized name: Insulin peglispro
DrugBank: Insulin peglispro (DB11567)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin peglispro
Study: 33622766
Drug: Epigallocatechin gallate
Normalized name: Epigallocatechin Gallate
DrugBank: Epigallocatechin gallate (DB12116)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epigallocatechin gallate (EGCG) treatment
Study: 33887262
Drug: Infliximab continued
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Infliximab continued (5 mg/kg every 8 weeks)
Study: 39577326
Drug: Enhanced Treatment
Normalized name: Thera-M Enhanced
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced Treatment as Usual (ETAU)
Study: 35797219
Drug: nab-paclitaxel 125
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: nab-paclitaxel 125 mg/m2 + gemcitabine
Study: 32988829
Drug: Oral acyclovir
Normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral acyclovir
Study: 33652093
Drug: Hospice representatives
Normalized name: chlorhexidine
DrugBank: Chlorhexidine (DB00878)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hospice representatives reporting knowledge and perceptions about medication shortages
Study: 35947046
Drug: Calcium channel
Normalized name: Calcium channel blocker
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium channel blockers
Study: 32730052
Drug: Imagine in
Normalized name: triclosan
DrugBank: Triclosan (DB08604)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Imagine in Daily Life
Study: 33378384
Drug: Low-dose ICS
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose ICS
Study: 32790733
Drug: Neither drug
Normalized name: 2,2',3,3',4,4',5,5',6-nonachlorodiphenyl either
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neither drug
Study: 32311110
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg dapagliflozin
Study: 35872530
Drug: Olaparib 300
Normalized name: Olaparib
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Olaparib 300 mg twice a day (BD)
Study: 39546129
Drug: Vehicle cream
Normalized name: vehicle cream base no.160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle cream
Study: 35428359
Drug: Peer coach
Normalized name: coachwhip stem extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peer coach intervention (CARE RA curriculum with assistance from a peer coach, weekly calls for 5 weeks)
Study: 33064597
Drug: Atrazine at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atrazine at concentrations of 2, 4, 8, 16, and 32 mg L‐1
Study: 33064597
Drug: Atrazine at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atrazine at concentrations of 0.18, 6, 12, and 18 mg L‐1 after air exposition stress
Study: 34330854
Drug: Usual physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual physical therapy (control)
Study: 32093665
Drug: Venturi mask
Normalized name: MASK
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Venturi mask (VM) oxygen therapy (15 L/min, FiO2 0.5) in good responders
Study: 38690606
Drug: Prednisolone 40
Normalized name: prednisolone 40 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone 40 mg daily
Study: 34820927
Drug: Aspirin treatment
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin treatment
Study: 36108767
Drug: NAC monotherapy
Normalized name: NAC
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: NAC monotherapy
Study: 38844921
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no antibiotic treatment)
Study: 35462214
Drug: Conventional physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional physical therapy (CPT) for 4 weeks
Study: 34732660
Drug: Metformin (MET)
Normalized name: metformin / pioglitazone Oral Tablet [Actoplus Met]
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin (MET) - 500 mg three times a day (TID)
Study: 38127508
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual (TAU) alone
Study: 36222756
Drug: Medical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical treatment
Study: 33654425
Drug: Lidocaine patch
Normalized name: LIDOCAINE 40 mg TOPICAL PATCH [Lidocaine Patch]
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine patch 5%
Study: 33964254
Drug: Primary lung
Normalized name: beef lung preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primary lung resection before systemic treatment
Study: 33964254
Drug: Primary lung
Normalized name: beef lung preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primary lung resection after systemic treatment
Study: 38526550
Drug: Influenza vaccine
Normalized name: Influenza vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Influenza vaccine
Study: 35162339
Drug: Yohimbine hydrochloride
Normalized name: Yohimbine Hydrochloride
DrugBank: Yohimbine (DB01392)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yohimbine hydrochloride (YHM; 2.5 mg)
Study: 34018147
Drug: Combined lipid-lowering
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined lipid-lowering therapy (10 mg/day atorvastatin and 10 mg/day ezetimibe)
Study: 35323950
Drug: Aspirin use
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin use within the first day of hospitalization
Study: 33642523
Drug: Miconazole Gel
Normalized name: Miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Miconazole Gel
Study: 35396924
Drug: Branded domperidone
Normalized name: Domperidone
DrugBank: Domperidone (DB01184)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Branded domperidone tablet (reference) in fed state
Study: 32391656
Drug: n-3 FA-enriched
Normalized name: 22:6(n-3)
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-3 FA-enriched oral nutrition supplement (ONS) twice daily for 7 days before and after surgery
Study: 32391656
Drug: n-3 FA-enriched
Normalized name: 22:6(n-3)
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-3 FA-enriched oral nutrition supplement (ONS)
Study: 35356508
Drug: Letrozole 5
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Letrozole 5 mg/day
Study: 33822396
Drug: Intensive treatment
Normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive treatment (SBP <120 mmHg)
Study: 35343754
Drug: EN solution
Normalized name: Banophen Solution
DrugBank: Delorazepam (DB01511)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EN solution + probiotics + 90 ml of pectin
Study: 35718205
Drug: VLA2001 low
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: VLA2001 low dose
Study: 34986897
Drug: TAK228 plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK228 plus weekly paclitaxel chemotherapy
Study: 33241616
Drug: Tazarotene Cream
Normalized name: Tazarotene Cream
DrugBank: Tazarotene (DB00799)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tazarotene Cream
Study: 39238110
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment